1
|
Granda P, Villamañán E, Heinz S, Laorden D, Romero D, Añón JM, Carpio C, Sobrino C, Collada V, Domínguez-Ortega J, Herrero A, Quirce S, Álvarez-Sala R. Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. J Investig Allergol Clin Immunol 2024; 34:60-61. [PMID: 37357596 DOI: 10.18176/jiaci.0920] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/27/2023] Open
Affiliation(s)
- P Granda
- Pharmacy Department, Hospital Central de la Defensa Gómez- Ulla, Madrid, Spain
| | - E Villamañán
- Pharmacy Department, Hospital Universitario La Paz, Madrid, Spain
- IdiPAZ, Madrid, Spain
- Medicine Department, Universidad Autónoma de Madrid, Spain
| | - S Heinz
- Pharmacy Department, Hospital Central de la Defensa Gómez- Ulla, Madrid, Spain
| | - D Laorden
- IdiPAZ, Madrid, Spain
- Pulmonology Department, Hospital Universitario La Paz, Madrid, Spain
| | - D Romero
- IdiPAZ, Madrid, Spain
- Intensive Care Unit, Hospital Universitario La Paz, Instituto de Salud Carlos III, Madrid, Spain
| | - J M Añón
- IdiPAZ, Madrid, Spain
- CIBERES, Instituto de Salud Carlos III, Madrid, Spain
- Allergy Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - C Carpio
- IdiPAZ, Madrid, Spain
- Medicine Department, Universidad Autónoma de Madrid, Spain
- Pulmonology Department, Hospital Universitario La Paz, Madrid, Spain
| | - C Sobrino
- Pharmacy Department, Hospital Universitario La Paz, Madrid, Spain
- IdiPAZ, Madrid, Spain
| | - V Collada
- Pharmacy Department, Hospital Universitario La Paz, Madrid, Spain
- IdiPAZ, Madrid, Spain
| | - J Domínguez-Ortega
- IdiPAZ, Madrid, Spain
- Allergy Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - A Herrero
- Pharmacy Department, Hospital Universitario La Paz, Madrid, Spain
- IdiPAZ, Madrid, Spain
| | - S Quirce
- Allergy Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
| | - R Álvarez-Sala
- IdiPAZ, Madrid, Spain
- Medicine Department, Universidad Autónoma de Madrid, Spain
- Pulmonology Department, Hospital Universitario La Paz, Madrid, Spain
| |
Collapse
|
2
|
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol 2024; 166:417-418. [PMID: 38289531 DOI: 10.1007/s11060-024-04581-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Affiliation(s)
- L Gately
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
| | - C Mesía
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain
| | - J M Sepúlveda
- Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - S Del Barco
- Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain
| | - E Pineda
- Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain
| | - R Gironés
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - J Fuster
- Medical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain
| | - W Hong
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - M Dumas
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - S Gill
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia
| | - L M Navarro
- Medical Oncology Service, Hospital de Salamanca, Salamanca, Spain
| | - A Herrero
- Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain
| | - A Dowling
- Department of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia
| | - R de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - M A Vaz
- Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain
| | - M Alonso
- Medical Oncology Service, Hospital Virgen del Rocio, Seville, Spain
| | - Z Lwin
- Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - R Harrup
- Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia
| | - S Peralta
- Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain
| | - A Long
- Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia
| | - P Perez-Segura
- Medical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain
| | - E Ahern
- Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia
| | - C O Garate
- Medical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
| | - M Wong
- Department of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia
| | - R Campbell
- Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia
| | - K Cuff
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - R Jennens
- Department of Medical Oncology, Epworth Health, Richmond, VIC, Australia
| | - O Gallego
- Medical Oncology Service, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain
| | - C Underhill
- Department of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia
| | | | - M Covela
- Medical Oncology Service, Hospital Lucus Augusti, Lugo, Spain
| | - A Cooper
- Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia
| | - S Brown
- Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia
| | - M Rosenthal
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - J Torres
- Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia
| | - I M Collins
- Department of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia
| | - P Gibbs
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - C Balana
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain
- Badalona Applied Research Group in Oncology (B-ARGO), Institut Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| |
Collapse
|
3
|
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol 2024; 166:407-415. [PMID: 38153582 DOI: 10.1007/s11060-023-04513-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Accepted: 11/15/2023] [Indexed: 12/29/2023]
Abstract
PURPOSE The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials. Standard-of-care stipulates 6 months. However, in routine care, it is often extended to 12 months, despite lacking robust supporting data. METHODS GEINO14-01 (Spain) and EX-TEM (Australia) studies enrolled glioblastoma patients without progression at the end of 6 months post-radiation temozolomide. Participants were randomised 1:1 to six additional months of temozolomide or observation. Primary endpoint was 6-month progression free survival from date of randomisation (6mPFS). Secondary endpoints included overall survival (OS) and toxicity. 204 patients were required to detect an improvement in 6mPFS from 50 to 60% (80% power). Neither study recruited sufficient patients. We performed a combined analysis of individual patient data. RESULTS 205 patients were recruited: 159 in GEINO14-01 (2014-2018) and 46 in EX-TEM (2019-2022). Median follow-up was 20.0 and 14.5 months. Baseline characteristics were balanced. There was no significant improvement in 6mPFS (57.2% vs 64.0%, OR0.75, p = 0.4), nor across any subgroups, including MGMT methylated; PFS (HR0.92, p = 0.59, median 7.8 vs 9.7 months); or OS (HR1.03, p = 0.87, median 20.1 vs 19.4 months). During treatment extension, 64% experienced any grade adverse event, mainly fatigue and gastrointestinal (both 54%). Only a minority required treatment changes: 4.5% dose delay, 7.5% dose reduction, 1.5% temozolomide discontinuation. CONCLUSION For glioblastoma patients, extending post-radiation temozolomide from 6 to 12 months is well tolerated but does not improve 6mPFS. We could not identify any subset that benefitted from extended treatment. Six months should remain standard-of-care.
Collapse
Affiliation(s)
- L Gately
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
| | - C Mesía
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain
| | - J M Sepúlveda
- Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - S Del Barco
- Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain
| | - E Pineda
- Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain
| | - R Gironés
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - J Fuster
- Medical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain
| | - W Hong
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - M Dumas
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - S Gill
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia
| | - L M Navarro
- Medical Oncology Service, Hospital de Salamanca, Salamanca, Spain
| | - A Herrero
- Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain
| | - A Dowling
- Department of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia
| | - R de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - M A Vaz
- Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain
| | - M Alonso
- Medical Oncology Service, Hospital Virgen del Rocio, Seville, Spain
| | - Z Lwin
- Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - R Harrup
- Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia
| | - S Peralta
- Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain
| | - A Long
- Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia
| | - P Perez-Segura
- Medical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain
| | - E Ahern
- Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia
| | - C O Garate
- Medical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
| | - M Wong
- Department of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia
| | - R Campbell
- Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia
| | - K Cuff
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - R Jennens
- Department of Medical Oncology, Epworth Health, Richmond, VIC, Australia
| | - O Gallego
- Medical Oncology Service, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - C Underhill
- Department of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia
| | | | - M Covela
- Medical Oncology Service, Hospital Lucus Augusti, Lugo, Spain
| | - A Cooper
- Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia
| | - S Brown
- Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia
| | - M Rosenthal
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - J Torres
- Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia
| | - I M Collins
- Department of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia
| | - P Gibbs
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - C Balana
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain
- Badalona Applied Research Group in Oncology (B-ARGO), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain
| |
Collapse
|
4
|
Valladares A, Picossi S, Corrales-Guerrero L, Herrero A. The role of SepF in cell division and diazotrophic growth in the multicellular cyanobacterium Anabaena sp. strain PCC 7120. Microbiol Res 2023; 277:127489. [PMID: 37716126 DOI: 10.1016/j.micres.2023.127489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 08/23/2023] [Accepted: 09/09/2023] [Indexed: 09/18/2023]
Abstract
The cyanobacterium Anabaena forms filaments of cells that grow by intercalary cell division producing adjoined daughter cells connected by septal junction protein complexes that provide filament cohesion and intercellular communication, representing a genuine case of bacterial multicellularity. In spite of their diderm character, cyanobacterial genomes encode homologs of SepF, a protein normally found in Gram-positive bacteria. In Anabaena, SepF is an essential protein that localized to the cell division ring and the intercellular septa. Overexpression of sepF had detrimental effects on growth, provoking conspicuous alterations in cell morphology that resemble the phenotype of mutants impaired in cell division, and altered the localization of the division-ring. SepF interacted with FtsZ and with the essential FtsZ tether ZipN. Whereas SepF from unicellular bacteria generally induces the bundling of FtsZ filaments, Anabaena SepF inhibited FtsZ bundling, reducing the thickness of the toroidal aggregates formed by FtsZ alone and eventually preventing FtsZ polymerization. Thus, in Anabaena SepF appears to have an essential role in cell division by limiting the polymerization of FtsZ to allow the correct formation and localization of the Z-ring. Expression of sepF is downregulated during heterocyst differentiation, likely contributing to the inhibition of Z-ring formation in heterocysts. Finally, the localization of SepF in intercellular septa and its interaction with the septal-junction related proteins SepJ and SepI suggest a role of SepF in the formation or stability of the septal complexes that mediate cell-cell adhesion and communication, processes that are key for the multicellular behavior of Anabaena.
Collapse
Affiliation(s)
- A Valladares
- Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC and Universidad de Sevilla, Seville, Spain
| | - S Picossi
- Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC and Universidad de Sevilla, Seville, Spain
| | - L Corrales-Guerrero
- Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC and Universidad de Sevilla, Seville, Spain
| | - A Herrero
- Instituto de Bioquímica Vegetal y Fotosíntesis, CSIC and Universidad de Sevilla, Seville, Spain.
| |
Collapse
|
5
|
Herrero A, Aseguinolaza IR, Oleaga A, Garcia-Adeva AJ, Apiñaniz E, Garshev AV, Yapaskurt VO, Morozkin AV. Selecting optimal R 6TX 2 intermetallics (R = Gd, Tb, Dy; T = Mn, Fe, Co, Ni; X = Sb, Te) for magnetic refrigeration. Dalton Trans 2023; 52:5780-5797. [PMID: 37039014 DOI: 10.1039/d3dt00223c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
Abstract
A complete experimental study of the physical properties playing a relevant role in the magnetic refrigeration application (structural, magnetic, magnetocaloric and thermal) has been performed over nine selected Fe2P-type R6TX2 (R = Gd, Tb, Dy; T = Mn, Fe, Co, Ni; X = Sb, Te) intermetallic compounds, to work close to room temperature. Two magnetic phase transitions are observed for these materials: a paramagnetic to ferromagnetic transition in the range of 182-282 K and a spin reorientation transition in the range of 26-76 K. As a consequence, two peaks related to a direct magnetocaloric effect (DMCE) appear with the magnetic entropy change, generating a wide table-like plateau region in between both peaks, which is required to improve the efficiency of refrigerators following an Ericsson cycle. The highest magnetic entropy peak value for μ0ΔH = 5 T is found for Tb2Dy4FeSb2, with 7.72 J kg-1 K-1 around 182 K. For the same applied field the other compounds show moderate values around room temperature (2.88-4.53 J kg-1 K-1). However, the superposition of the two peaks results in huge refrigerant capacity values, up to RCFWHM(5 T) = 1103.04 J kg-1 in the case of Tb2Dy4FeSb2. The thermal diffusivity, thermal effusivity, thermal conductivity and specific heat capacity have been measured at room temperature, and the temperature dependence of the former has been obtained around the relevant magnetic phase transition region, with values in the range of 1.3-2.3 mm2 s-1, which are good for magnetic refrigerators at high working frequencies. The study is completed with a rigorous critical behavior analysis of the second order PM-FM transition. The critical exponent γ points to long range order interactions, in general, while β values are in the range of 0.59-0.90, indicating a deviation from theoretical models as a reflection of the magnetic complexity in these compounds. The critical exponents have been used to confirm the scaling relations of magnetocaloric properties, and the scaling of refrigerant capacity (RC) values in materials exhibiting two magnetic phase transitions is addressed, concluding that for a correct scaling of RC the magnetic entropy change peak must be considered symmetric. The role of each atom in the properties of the compounds is discussed.
Collapse
Affiliation(s)
- A Herrero
- Departamento de Física Aplicada, Escuela de Ingeniería de Bilbao, Universidad del País Vasco UPV/EHU, Plaza Torres Quevedo 1, 48013 Bilbao, Spain.
| | - I R Aseguinolaza
- Departamento de Física Aplicada, Escuela de Ingeniería de Bilbao, Universidad del País Vasco UPV/EHU, Plaza Torres Quevedo 1, 48013 Bilbao, Spain.
| | - A Oleaga
- Departamento de Física Aplicada, Escuela de Ingeniería de Bilbao, Universidad del País Vasco UPV/EHU, Plaza Torres Quevedo 1, 48013 Bilbao, Spain.
| | - A J Garcia-Adeva
- Departamento de Física Aplicada, Escuela de Ingeniería de Bilbao, Universidad del País Vasco UPV/EHU, Plaza Torres Quevedo 1, 48013 Bilbao, Spain.
| | - E Apiñaniz
- Departamento de Física Aplicada, Escuela de Ingeniería de Bilbao, Universidad del País Vasco UPV/EHU, Plaza Torres Quevedo 1, 48013 Bilbao, Spain.
| | - A V Garshev
- Department of Chemistry, Moscow State University, Lenisnkie Gory, House 1, Building 3, Moscow, GSP-2, 119991, Russia
| | - V O Yapaskurt
- Department of Petrology, Geological Faculty, Moscow State University, Leninskie Gory, Moscow, 119991, Russia
| | - A V Morozkin
- Department of Chemistry, Moscow State University, Lenisnkie Gory, House 1, Building 3, Moscow, GSP-2, 119991, Russia
| |
Collapse
|
6
|
Yélamos O, Andersen D, Pont M, Iglesias P, Potrony M, Domínguez M, Herrero A, Alejo B, Mateu J, Røpke M, Danneskiold-Samsøe NB, Malvehy J, Guy RH, Brix S, Puig S. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. Clin Exp Dermatol 2023; 48:80-88. [PMID: 36730521 DOI: 10.1093/ced/llac040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 09/17/2022] [Accepted: 11/03/2022] [Indexed: 01/11/2023]
Abstract
BACKGROUND Molecular skin profiling techniques, typically performed on skin samples taken by punch biopsy, have enhanced the understanding of the pathophysiology of atopic dermatitis (AD), thereby enabling the development of novel targeted therapeutics. However, punch biopsies are not always feasible or desirable, and novel minimally invasive methods such as skin tape stripping have been developed. AIM To develop, optimize and validate a novel tape stripping method guided by noninvasive in vivo skin imaging to sample atopic skin in children. METHODS Skin tape stripping-based procedures were compared and optimized using data from 30 healthy controls (HCs: 5 adults, 25 children) and 39 atopic children. Evaluations were guided by high-resolution photography, reflectance confocal microscopy, optical coherence tomography and transepidermal water loss measurements. We assessed and compared adverse events (AEs), the time needed to perform the sampling and the cDNA levels obtained from the tapes. RESULTS Tape stripping methods based on previously described protocols resulted in erosions in all participants and required a median time of 65 min to perform (range 60-70 min), but provided good cDNA yield. Shorter durations appeared less invasive but provided lower cDNA yield. The final optimized tape stripping protocol, using 11 tapes of 22 mm in diameter, each applied twice for 5 s with 90° rotation, did not produce significant AEs, was completed within a median time of 7 min (range 5-15 min) and provided good cDNA yield both in HCs and atopic children. CONCLUSION Our minimally invasive method is safe and reliable, and provides reproducible acquisition of cDNA in atopic children. In addition, it enables rapid sample collection, a crucial factor in clinical practice.
Collapse
Affiliation(s)
- O Yélamos
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.,Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IIB SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - D Andersen
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - M Pont
- Almirall R&D, Barcelona, Spain
| | - P Iglesias
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - M Potrony
- Biochemistry and Molecular Genetics Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - M Domínguez
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - A Herrero
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - B Alejo
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - J Mateu
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - M Røpke
- LeoPharma A/S, Ballerup, Denmark
| | | | - J Malvehy
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - R H Guy
- Department of Life Sciences, University of Bath, Bath, Somerset, UK
| | - S Brix
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
| | - S Puig
- Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
7
|
Villamañán E, Fernández de Uzquiano E, García E, Sobrino C, del Pozo A, Carpio C, Herrero A, Armada E, Álvarez-Sala R, Castro A. Liderazgo de la mujer en la investigación clínica: estudio observacional retrospectivo durante dos décadas en España. Rev Clin Esp 2022. [DOI: 10.1016/j.rce.2022.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
8
|
Souche R, Mas S, Scatton O, Fabre JM, Gimeno L, Herrero A, Gaujoux S. French legislation on retrospective clinical research: What to know and what to do. J Visc Surg 2022; 159:222-228. [DOI: 10.1016/j.jviscsurg.2021.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Olivares E, Ye H, Herrero A, Nia BA, Ren Y, Donovan R, Flaviis F. Applications of information channels to physics-informed neural networks for WiFi signal propagation simulation at the edge of the industrial internet of things. Neurocomputing 2021. [DOI: 10.1016/j.neucom.2021.04.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Valverde-Som L, Reguera C, Herrero A, Sarabia L, Ortiz M. Determination of polymer additive residues that migrate from coffee capsules by means of stir bar sorptive extraction-gas chromatography-mass spectrometry and PARAFAC decomposition. Food Packag Shelf Life 2021. [DOI: 10.1016/j.fpsl.2021.100664] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Herrero A, Gonot Gaschard M, Bouyabrine H, Perrey J, Picot MC, Guillon F, Fabre JM, Souche R, Navarro F. Comparative study of biological versus synthetic prostheses in the treatment of ventral hernias classified as grade II/III by the Ventral Hernia Working Group. J Visc Surg 2021; 159:98-107. [PMID: 34020911 DOI: 10.1016/j.jviscsurg.2021.02.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIM OF THE STUDY The implantation of biological prostheses in an at-risk environment has seen increasing use. Their markedly higher cost compared to synthetic prostheses makes it important to analyse their usefulness in terms of actual benefit and cost-effectiveness. This study aims to examine the relevance of bioprostheses during surgical repair of Grade II/III ventral hernias as classified by the Ventral hernia working group (VHWG). MATERIALS AND METHODS This study analysed the data of 119 patients requiring non-emergency repair of VHWG II/III grade hernias between 2010 and 2017. The results of patients who were treated with a bioprosthesis (n=59) were compared to those receiving a synthetic prosthesis (n=60). The primary outcome was surgical site infection (SSI) at 90 days. The secondary endpoints were hernia recurrence rate, cost of the prosthesis, duration of hospital stay and re-hospitalisation rate. RESULTS The two groups were shown to be comparable by analysis of demographic, pre- and intraoperative data. The SSI rate was significantly higher in the bioprosthesis group (20% vs. 7%; P=0.010), as was the recurrence rate (56% vs. 28%; P=0.003) with a median follow-up of 40 months. The cost of the bioprosthesis was significantly higher than that of the synthetic prosthesis (€3363 vs. €249; P<0.010). CONCLUSION In this retrospective study, the use of a bioprosthesis for repair of VHWG II/III ventral hernias was associated with a higher rate of both SSI and hernia recurrence at a cost 13 times greater than the use of a synthetic prosthesis.
Collapse
Affiliation(s)
- A Herrero
- Department of digestive surgery and liver transplantation, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France.
| | - M Gonot Gaschard
- Department of digestive surgery and liver transplantation, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - H Bouyabrine
- Department of digestive surgery and liver transplantation, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | - J Perrey
- Pharmacie euromédecine, CHU de Montpellier, correspondant local de matériovigilance, équipe des dispositifs médicaux stériles, 34295 Montpellier, France
| | - M-C Picot
- Department of medical information, Clinical research and epidemiology unit, hôpital de la Colombière, CHU de Montpellier, 34295 Montpellier, France
| | - F Guillon
- Department of digestive surgery, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France
| | - J-M Fabre
- Department of digestive surgery, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France
| | - R Souche
- Department of digestive surgery, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France
| | - F Navarro
- Department of digestive surgery and liver transplantation, University of Montpellier, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| |
Collapse
|
12
|
Yélamos O, Andersen D, Iglesias P, Potrony M, Dominguez M, Herrero A, Alejo B, Mateu J, Røpke M, Pont Giralt M, Banhos Danneskiold-Samsøe N, Kristiansen K, Malvehy J, Guy R, Brix S, Puig S. 130 Development of a minimally-invasive method, guided by in vivo non-invasive imaging, to sample atopic skin. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Ortiz M, Sarabia L, Herrero A, Reguera C, Sanllorente S, Arce M, Valencia O, Ruiz S, Sánchez M. Partial least squares model inversion in the chromatographic determination of triazines in water. Microchem J 2021. [DOI: 10.1016/j.microc.2021.105971] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
14
|
Lopez Guerrero J, Mendiola M, Pérez-Fidalgo J, Romero I, Gomez Raposo C, Herrero A, Alarcon J, Esteban Esteban C, Marquina Ospina G, Rubio M, Sanchez L, Guerra E, González Martín A. 854P A multicenter clinical registry with associated biological samples of gynecological cancer patients: Pilot study of the Spanish Ovarian Cancer Research Group (GEICO 81-T). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Colombo N, Gantzer J, Ataseven B, Cropet C, Scambia G, Herrero A, Sevelda P, Kobayashi H, Vuylsteke P, Mirza M, Priou F, Buderath P, Pisano C, Lainez N, Guillemet C, Burges A, Sverdlin R, El-Balat A, Raban N, Ray-Coquard I. 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.951] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N, Domínguez M, Iglesias P, Herrero A, Malvehy J, Puig S. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial. J Eur Acad Dermatol Venereol 2020; 35:143-149. [PMID: 32365242 PMCID: PMC7818495 DOI: 10.1111/jdv.16559] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Accepted: 04/10/2020] [Indexed: 01/07/2023]
Abstract
BACKGROUND Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment. OBJECTIVES To compare the clinical and non-invasive microscopic features in a psoriatic target lesion treated with clobetasol cream or calcipotriol/betamethasone dipropionate foam (Cal/BD foam). METHODS Prospective, unicentric, open, randomized clinical trial comparing clinical data [total clinical score (TCS)] and microscopic data (dermoscopy, RCM and OCT) in psoriasis patients treated with clobetasol or Cal/BD foam. RESULTS We included 36 adult patients (22 men). At week 4, more patients treated with Cal/BD foam achieved TCS ≤1 than with clobetasol (63.2% vs. 18.8%, P = 0.016). Treatment satisfaction was higher with Cal/BD foam (P < 0.03). Microscopically, Cal/BD foam induced more reduction in epidermal thickness at week 4 (P < 0.049). Dilated horizontal blood vessels were more common with clobetasol than with Cal/BD foam at week 8 (69.2% vs. 31.2%, P = 0.159). If epidermal hyperplasia was noted at baseline, the response was poorer with clobetasol (P = 0.029). LIMITATIONS Small sample size, open study, imaging sampling bias. CONCLUSION Cal/BD foam is more effective than clobetasol, has better patient satisfaction and induces greater reduction in the hyperkeratosis/acanthosis, regardless of baseline epidermal hyperplasia.
Collapse
Affiliation(s)
- O Yélamos
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.,Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain.,Department of Dermatology, Centro Médico Teknon - Quirónsalud, Barcelona, Spain
| | - B Alejo
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - S S Ertekin
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - L Villa-Crespo
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - S Zamora-Barquero
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - N Martinez
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - M Domínguez
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - P Iglesias
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - A Herrero
- Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
| | - J Malvehy
- CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain
| | - S Puig
- CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
17
|
Villamañán E, Herrero A, Álvarez-Sala R, Quirce S. Multidisciplinary Severe Asthma Management: The Role of Hospital Pharmacists in Accredited Specialized Adult Asthma Units in Spain. J Investig Allergol Clin Immunol 2020; 30:305-306. [PMID: 31983677 DOI: 10.18176/jiaci.0488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E Villamañán
- Pharmacy Department, La Paz University Hospital. IdiPAZ, Madrid, Spain
| | - A Herrero
- Pharmacy Department, La Paz University Hospital. IdiPAZ, Madrid, Spain
| | - R Álvarez-Sala
- Pneumology Department, La Paz University Hospital, IdiPAZ, Madrid, Spain
| | - S Quirce
- Allergy Department, La Paz University Hospital, IdiPAZ, Madrid, Spain
| |
Collapse
|
18
|
González-Santiago S, Ramón y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-del-Alba A. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019). Clin Transl Oncol 2019; 22:193-200. [DOI: 10.1007/s12094-019-02262-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Accepted: 12/05/2019] [Indexed: 12/17/2022]
Abstract
AbstractMutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes included in multigene panels have increased the genetic diagnosis of hereditary breast and ovarian cancer families by 50%. Multigene cancer panels provide new challenges related to increased frequency of variants of uncertain significance, new gene-specific cancer risk assessments, and clinical recommendations for carriers of mutations of new genes. Although clinical criteria for genetic testing continue to be largely based on personal and family history with around a 10% detection rate, broader criteria are being applied with a lower threshold for detecting mutations when there are therapeutic implications for patients with breast or ovarian cancer. In this regard, new models of genetic counselling and testing are being implemented following the registration of PARP inhibitors for individuals who display BRCA mutations. Massive sequencing techniques in tumor tissue is also driving a paradigm shift in genetic testing and potential identification of germline mutations. In this paper, we review the current clinical criteria for genetic testing, as well as surveillance recommendations in healthy carriers, risk reduction surgical options, and new treatment strategies in breast cancer gene-mutated carriers.
Collapse
|
19
|
Javed S, Benoist S, De Fouchardiere CL, Truant S, Sefrioui D, Galais M, Hautefeuille V, Artru P, Guimbaud R, Cohen R, Lievre A, Edeline J, Bachet JB, Gelli M, Herrero A, Marchese U, Amrani ME, Devos P, Turpin A, Ploquin A. BRAF-mutated colorectal metastases: What is the benefit of liver surgery? Results from a cohort of 91 patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Balana C, Sepulveda J, Pineda E, Vaz M, Mesia C, Fuster J, Girones R, Muñoz-Langa J, Navarro M, Alonso M, Gil Gil M, Herrero A, Estival A, Gallego O, Peralta S, Olier C, Pérez-Segura P, Covela M, Martinez García M, Domenech M, Carrato C, Sanz C, Velarde J, Berrocal A, Luque R, De las Peñas R, Del Barco S. P14.58 Extending adjuvant temozolomide longer than six cycles doesn’t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01 trial (NCT02209948) investigated the role of extending adjuvant TMZ to 12 cycles in a randomized multicenter study.
MATERIAL AND METHODS
Between Aug/2014 and Nov/2018, 166 patients (p) were screened and 159 randomized to extend (80p) or not (79p) TMZ treatment to 12 cycles after proving stable disease in the MRI performed before inclusion. The trial was stratified by MGMT status and presence or absence of residual disease (defined as a residual enhancement larger than 1cm on the MRI). The primary endpoint was differences in 6monthsPFS, secondary endpoints were differences in PFS, OS, toxicity, between arms and per stratification factors.
RESULTS
Median age was 60.4 (range 29–83), 97p (61%) were methylated and 83 p (52.2%) were reported with residual disease. Median (m) PFS was 7.9 months (95%CI: 6.1–9.8) and mOS: 20.9 (95%CI: 17.6–24.1). A methylated status was a factor of better PFS (HR=0.29, 95% CI 0.46–0.95; p=0.029) and better OS (HR= 0.43: 95% CI 0.28–0.66; p=0.000) as well as the absence of residual disease (PFS: HR = 0.84: 95% CI =0.71–1.01; p=0.068; OS: HR=0.77, 95%CI 0.63–0.96; p=0.019). We didn’t find any difference in PFS (HR=1.02, 95%CI 0.85–1.21; p=0.82), or OS (HR=0.90; 0.73–1.11; p=0.34) on extending treatment with temozolomide longer than 6 cycles.
CONCLUSION
There is no benefit of continuing TMZ treatment for more than 6 cycles in the adjuvant treatment of glioblastoma. Final data will be presented at the congress. Supported by a Grant of the ISCIII: PI13/01751
Collapse
Affiliation(s)
- C Balana
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - J Sepulveda
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | - E Pineda
- Hospital Clinic de Barcelona, Barcelona, Spain
| | - M Vaz
- Hospital Ramon y Cajal, Madrid, Spain
| | - C Mesia
- Institut Catala Oncologia Hospital Duran y Reynalds, Hospitalet de Llobregat, Spain
| | - J Fuster
- Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - R Girones
- Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - J Muñoz-Langa
- Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - M Navarro
- Hospital Universitario de Salamanca, Salamanca, Spain
| | - M Alonso
- Hospital Universitario la Virgen del Rocio, Sevilla, Spain
| | - M Gil Gil
- Institut Catala Oncologia Hospital Duran y Reynalds, Hospitalet de Llobregat, Spain
| | - A Herrero
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - A Estival
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - O Gallego
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Peralta
- Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - C Olier
- Hospital Universitario Fundacion Alcorcon, Alcorcon, Spain
| | | | - M Covela
- Hospital Universitario Lucus Augusti, Lugo, Spain
| | | | - M Domenech
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - C Carrato
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - C Sanz
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - J Velarde
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - A Berrocal
- Hospital General Universitari de Valencia, Valencia, Spain
| | - R Luque
- HospitalUniversitario Virgen de las Nieves, Granada, Spain
| | | | - S Del Barco
- Institut Catala Oncologia Hospital Universitari Josep Trueta, Girona, Spain
| |
Collapse
|
21
|
Bachet JB, Moreno-Lopez N, Vigano L, Marchese U, Gelli M, Raoux L, Truant S, Laurent C, Herrero A, Le Roy B, Deguelte Lardiere S, Passot G, Hautefeuille V, De La Fouchardiere C, Artru P, Ameto T, Mabrut JY, Schwarz L, Rousseau B, Lepère C, Coriat R, Brouquet A, Sa Cunha A, Benoist S. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. Br J Surg 2019; 106:1237-1247. [PMID: 31183866 DOI: 10.1002/bjs.11180] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 02/15/2019] [Accepted: 02/18/2019] [Indexed: 12/17/2022]
Abstract
BACKGROUND BRAF mutation is associated with a poor prognosis in patients with metastatic colorectal cancer. For patients with resectable colorectal liver metastases (CRLMs), the prognostic impact of BRAF mutation is unknown and the benefit of surgery debated. This nationwide intergroup (ACHBT, FRENCH, AGEO) study aimed to evaluate the oncological outcome of patients undergoing liver resection for BRAF-mutated CRLMs. METHODS The study included patients who underwent resection for BRAF-mutated CRLMs in 24 centres between 2012 and 2016. A case-matched comparison was made with 183 patients who underwent resection of CRLMs with wild-type BRAF during the same interval. RESULTS Sixty-six patients who underwent resection for BRAF-mutated CRLMs in 24 centres were compared with 183 patients with wild-type BRAF. The 1- and 3-year disease-free survival (DFS) rates were 46 and 19 per cent for the BRAF-mutated group, and 55·4 and 27·8 per cent for the group with wild-type BRAF (P = 0·430). In multivariable analysis, BRAF mutation was not associated with worse DFS (hazard ratio 1·16, 95 per cent c.i. 0·72 to 1·85; P = 0·547). The 1- and 3-year overall survival rates after surgery were 94 and 54 per cent respectively among patients with BRAF mutation, and 95·8 and 82·9 per cent in those with wild-type BRAF (P = 0·004). Median survival after disease progression was 23·0 (95 per cent c.i. 11·0 to 35·0) months among patients with mutated BRAF and 44·3 (35·9 to 52·6) months in those with wild-type BRAF (P = 0·050). Multisite disease progression was more common in the BRAF-mutated group (48 versus 29·8 per cent; P = 0·034). CONCLUSION These results support surgical treatment for resectable BRAF-mutated CRLM, as BRAF mutation by itself does not increase the risk of relapse after resection. BRAF mutation is associated with worse survival in patients whose disease relapses after resection of CRLM, as for non-metastatic colorectal cancer.
Collapse
Affiliation(s)
- J-B Bachet
- Sorbonne Université, University Pierre and Marie Curie, Paris, France.,Department of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - N Moreno-Lopez
- Department of Digestive Surgery, Dijon University Hospital, Dijon, France
| | - L Vigano
- Division of Hepatobiliary and General Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - U Marchese
- Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - M Gelli
- Department of General Surgical Oncology, Gustave Roussy Institute, Villejuif, France
| | - L Raoux
- Department of Digestive Surgery, University Hospital of Toulouse, University Paul Sabatier, Toulouse, France
| | - S Truant
- Department of Digestive Surgery and Transplantation, Lille University Hospital, Lille, France
| | - C Laurent
- Department of Hepatobiliopancreatic Surgery and Liver Transplantation, Saint André Hospital, Bordeaux, France
| | - A Herrero
- Department of General Surgery, Division of Transplantation, University of Montpellier - College of Medicine, Saint Eloi Hospital, Montpellier, France
| | - B Le Roy
- Department of Digestive Surgery, Estaing University Hospital, Clermont-Ferrand, France
| | - S Deguelte Lardiere
- Department of Hepato-Gastroenterology and Digestive Oncology, Robert-Debré University Hospital, Reims, France
| | - G Passot
- Department of Surgical Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France
| | - V Hautefeuille
- Department of Gastroenterology, Amiens-Picardie University Hospital, Amiens, France
| | | | - P Artru
- Department of Oncology, Hôpital Privé Jean Mermoz, Lyon, France
| | - T Ameto
- Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France
| | - J Y Mabrut
- Department of Hepatobiliopancreatic Surgery and Liver Transplantation, Hôpital Croix Rousse, Lyon, France
| | - L Schwarz
- Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen, France
| | - B Rousseau
- Department of Oncology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - C Lepère
- Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, AP-HP, Paris, France
| | - R Coriat
- Department of Gastroenterology and Digestive Oncology, Cochin Hospital, AP-HP, Paris, France
| | - A Brouquet
- Department of Digestive Surgery and Surgical Oncology, Bicêtre Hospital, AP-HP, Paris-Sud University, Le Kremlin Bicêtre, France.,Paris-Sud University, Le Kremlin Bicêtre, France
| | - A Sa Cunha
- Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Paul Brousse Hospital, Villejuif, France.,Paris-Sud University, Le Kremlin Bicêtre, France
| | - S Benoist
- Department of Digestive Surgery and Surgical Oncology, Bicêtre Hospital, AP-HP, Paris-Sud University, Le Kremlin Bicêtre, France.,Paris-Sud University, Le Kremlin Bicêtre, France
| |
Collapse
|
22
|
Grau Amorós J, Formiga F, Aramburu Bodas O, Armengou Arxe A, Conde Martel A, Quesada Simón M, Oropesa Juanes R, Satué Bartolomé J, Dávila Ramos M, Montero Pérez-Barquero M, Anarte L, Aramburu O, Arévalo-Lorido J, Armengou A, Brase A, Carrascosa S, Carrera M, Casado J, Cerqueiro J, Conde A, Dávila M, Díez-Manglano J, Epelde F, Formiga F, Franco J, Gallego J, García-Escrivá D, González-Franco A, Grau J, Guisado M, Herrero A, Llacer P, López-Castellanos G, Manzano L, Martínez-Zapico A, Montero-Pérez-Barquero M, Muela A, Oropesa R, Pérez-Bocanegra C, Pérez-Calvo J, Pérez-Silvestre J, Quesada M, Quirós R, Rodríguez-Ávila E, Ruiz-Laiglesia F, Ruiz-Ortega R, Salamanca P, Sánchez-Marteles M, Satué J, Serrado A, Suárez I, Trullàs J. Hemoconcentración como predictor de supervivencia al año de ingreso por insuficiencia cardiaca aguda en el registro RICA. Rev Clin Esp 2019; 219:1-9. [DOI: 10.1016/j.rce.2018.07.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 07/05/2018] [Accepted: 07/06/2018] [Indexed: 02/04/2023]
|
23
|
Grau Amorós J, Formiga F, Aramburu Bodas O, Armengou Arxe A, Conde Martel A, Quesada Simón M, Oropesa Juanes R, Satué Bartolomé J, Dávila Ramos M, Montero Pérez-Barquero M, Anarte L, Aramburu O, Arévalo-Lorido J, Armengou A, Brase A, Carrascosa S, Carrera M, Casado J, Cerqueiro J, Conde A, Dávila M, Díez-Manglano J, Epelde F, Formiga F, Franco J, Gallego J, García-Escrivá D, González-Franco A, Grau J, Guisado M, Herrero A, Llacer P, López-Castellanos G, Manzano L, Martínez-Zapico A, Montero-Pérez-Barquero M, Muela A, Oropesa R, Pérez-Bocanegra C, Pérez-Calvo J, Pérez-Silvestre J, Quesada M, Quirós R, Rodríguez-Ávila E, Ruiz-Laiglesia F, Ruiz-Ortega R, Salamanca P, Sánchez-Marteles M, Satué J, Serrado A, Suárez I, Trullàs J. Hemoconcentration as a prognostic factor after hospital discharge in acute heart failure in the RICA registry. Rev Clin Esp 2019. [DOI: 10.1016/j.rceng.2018.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
24
|
Herrero A, Thompson KD, Ashby A, Rodger HD, Dagleish MP. Complex Gill Disease: an Emerging Syndrome in Farmed Atlantic Salmon (Salmo salar L.). J Comp Pathol 2018; 163:23-28. [PMID: 30213370 DOI: 10.1016/j.jcpa.2018.07.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 07/05/2018] [Accepted: 07/18/2018] [Indexed: 11/19/2022]
Abstract
Gill disorders have become a significant problem during the marine phase of farming Atlantic salmon (Salmo salar L.). The term complex gill disease (CGD) includes a wide range of clinical gill disease presentations generally occurring from the end of summer to early winter on marine Atlantic salmon farms. The gross and histological lesions observed are the resultant culmination of exposure to a mixture of environmental insults, pathogenic organisms and farm management practices. None of the three principal agents purportedly associated with CGD (Desmozoon lepeophtherii, salmon gill poxvirus or Candidatus Branchiomonas cysticola) have been cultured successfully in-vitro, so individual in-vivo challenge studies to identify their pathogenesis have not been possible. Studies of cohabitation of single pathogen-infected fish with naïve fish, and epidemiological investigations are required urgently to elucidate the roles of these pathogens and other factors in CGD.
Collapse
Affiliation(s)
- A Herrero
- Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Scotland, United Kingdom
| | - K D Thompson
- Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Scotland, United Kingdom
| | - A Ashby
- Fish Vet Group Ltd., 22 Carsegate Road, Inverness, Scotland, UK
| | - H D Rodger
- Fish Vet Group Ireland, Unit 7b Oranmore Business Park, Oranmore, Co. Galway, Ireland
| | - M P Dagleish
- Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Scotland, United Kingdom.
| |
Collapse
|
25
|
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin Transl Oncol 2018; 20:1529-1537. [PMID: 29737461 DOI: 10.1007/s12094-018-1883-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 04/23/2018] [Indexed: 11/29/2022]
Abstract
PURPOSE We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients. PATIENTS AND METHODS We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy. RESULTS OS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P = 0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P = 0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P = 0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor. CONCLUSION In our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
Collapse
Affiliation(s)
- C Balaña
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain.
| | - A Estival
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain
| | - I Teruel
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain
| | - M Hardy-Werbin
- Cancer Research Programm, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - J Sepulveda
- Medical Oncology Service, Hospital Universitario, 12 de Octubre, Madrid, Spain
| | - E Pineda
- Medical Oncology Service, Hospital Clinic Provincial, Barcelona, Spain
| | | | - O Gallego
- Medical Oncology Service, Hospital de Sant Pau, Barcelona, Spain
| | - R Luque
- Medical Oncology Service, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - M Gil-Gil
- Medical Oncology Service, Institut Català d'Oncologia-IDIBELL, Hospitalet de Llobregat, Spain
| | - C Mesia
- Medical Oncology Service, Institut Català d'Oncologia-IDIBELL, Hospitalet de Llobregat, Spain
| | - S Del Barco
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain
| | - A Herrero
- Medical Oncology Service, Hospital Miguel Servet, Saragossa, Spain
| | - A Berrocal
- Medical Oncology Service, Hospital General Universitario de Valencia, Valencia, Spain
| | - P Perez-Segura
- Medical Oncology Service, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - R De Las Penas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - J Marruecos
- Radiation Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain
| | - R Fuentes
- Radiation Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain
| | - G Reynes
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - J M Velarde
- Institut Investigació Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Spain
| | - A Cardona
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.,Foundation for Clinical and Applied Cancer Research, FICMAC, Bogotá, Colombia.,Biology Systems Department, Universidad el Bosque, Bogotá, Colombia
| | - E Verger
- Radiation Oncology Service, Hospital Clinic Provincial, Barcelona, Spain
| | - C Panciroli
- Institut Investigació Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Spain
| | - S Villà
- Radiation Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
26
|
Abstract
Aims and Background Brain metastases are an unusual finding in patients with colorectal carcinoma. We wished to determine the clinical presentation, the time interval between the diagnosis of colorectal carcinoma and the appearance of brain metastases, and the overall survival. Patient characteristics The median age of our patients was 61 years. Brain metastases developed subsequently to the diagnosis of colorectal cancer in nine patients. All patients had neurologic symptoms. All patients had progressing systemic disease at the moment of intracranial presentation. Four patients received whole brain radiation therapy. The median survival was 11 weeks. Discussion The development of brain metastasis is a late event in the course of colorectal carcinoma and occurs most often in patients with extensive systemic disease that contraindi-cates surgical resection. Radiotherapy can improve the survival of this group of patients whereas the role of chemotherapy is still unclear due to the low frequency of such cases.
Collapse
Affiliation(s)
- M Zorrilla
- Division of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Schneider FRN, Sana H, Evans CJ, Bestenlehner JM, Castro N, Fossati L, Gräfener G, Langer N, Ramírez-Agudelo OH, Sabín-Sanjulián C, Simón-Díaz S, Tramper F, Crowther PA, de Koter A, de Mink SE, Dufton PL, Garcia M, Gieles M, Hénault-Brunet V, Herrero A, Izzard RG, Kalari V, Lennon DJ, Maíz Apellániz J, Markova N, Najarro F, Podsiadlowski P, Puls J, Taylor WD, van Loon JT, Vink JS, Norman C. An excess of massive stars in the local 30 Doradus starburst. Science 2018; 359:69-71. [PMID: 29302009 DOI: 10.1126/science.aan0106] [Citation(s) in RCA: 127] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 11/30/2017] [Indexed: 11/02/2022]
Abstract
The 30 Doradus star-forming region in the Large Magellanic Cloud is a nearby analog of large star-formation events in the distant universe. We determined the recent formation history and the initial mass function (IMF) of massive stars in 30 Doradus on the basis of spectroscopic observations of 247 stars more massive than 15 solar masses ([Formula: see text]). The main episode of massive star formation began about 8 million years (My) ago, and the star-formation rate seems to have declined in the last 1 My. The IMF is densely sampled up to 200 [Formula: see text] and contains 32 ± 12% more stars above 30 [Formula: see text] than predicted by a standard Salpeter IMF. In the mass range of 15 to 200 [Formula: see text], the IMF power-law exponent is [Formula: see text], shallower than the Salpeter value of 2.35.
Collapse
Affiliation(s)
- F R N Schneider
- Department of Physics, University of Oxford, Keble Road, Oxford OX1 3RH, UK
| | - H Sana
- Institute of Astrophysics, KU Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - C J Evans
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - J M Bestenlehner
- Max-Planck-Institut für Astronomie, Königstuhl 17, 69117 Heidelberg, Germany.,Department of Physics and Astronomy, Hicks Building, Hounsfield Road, University of Sheffield, Sheffield S3 7RH, UK
| | - N Castro
- Department of Astronomy, University of Michigan, 1085 South University Avenue, Ann Arbor, MI 48109, USA
| | - L Fossati
- Austrian Academy of Sciences, Space Research Institute, Schmiedlstraße 6, 8042 Graz, Austria
| | - G Gräfener
- Argelander-Institut für Astronomie der Universität Bonn, Auf dem Hügel 71, 53121 Bonn, Germany
| | - N Langer
- Argelander-Institut für Astronomie der Universität Bonn, Auf dem Hügel 71, 53121 Bonn, Germany
| | - O H Ramírez-Agudelo
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - C Sabín-Sanjulián
- Departamento de Física y Astronomía, Universidad de La Serena, Avenida Juan Cisternas no. 1200 Norte, La Serena, Chile
| | - S Simón-Díaz
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - F Tramper
- European Space Astronomy Centre, Mission Operations Division, P.O. Box 78, 28691 Villanueva de la Cañada, Madrid, Spain
| | - P A Crowther
- Department of Physics and Astronomy, Hicks Building, Hounsfield Road, University of Sheffield, Sheffield S3 7RH, UK
| | - A de Koter
- Astronomical Institute Anton Pannekoek, Amsterdam University, Science Park 904, 1098 XH Amsterdam, Netherlands.,Institute of Astrophysics, KU Leuven, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - S E de Mink
- Astronomical Institute Anton Pannekoek, Amsterdam University, Science Park 904, 1098 XH Amsterdam, Netherlands
| | - P L Dufton
- Astrophysics Research Centre, School of Mathematics and Physics, Queen's University Belfast, Belfast BT7 1NN, Northern Ireland, UK
| | - M Garcia
- Centro de Astrobiología, CSIC-INTA, Carretera de Torrejón a Ajalvir km-4, E-28850 Torrejón de Ardoz, Madrid, Spain
| | - M Gieles
- Department of Physics, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, GU2 7XH, UK
| | - V Hénault-Brunet
- National Research Council, Herzberg Astronomy and Astrophysics, 5071 West Saanich Road, Victoria, British Columbia V9E 2E7, Canada.,Department of Astrophysics/Institute for Mathematics, Astrophysics and Particle Physics, Radboud University, P.O. Box 9010, NL-6500 GL Nijmegen, Netherlands
| | - A Herrero
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - R G Izzard
- Department of Physics, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, GU2 7XH, UK.,Institute of Astronomy, The Observatories, Madingley Road, Cambridge CB3 0HA, UK
| | - V Kalari
- Departamento de Astronomía, Universidad de Chile, Camino El Observatorio 1515, Las Condes, Santiago, Casilla 36-D, Chile
| | - D J Lennon
- European Space Astronomy Centre, Mission Operations Division, P.O. Box 78, 28691 Villanueva de la Cañada, Madrid, Spain
| | - J Maíz Apellániz
- Centro de Astrobiología, CSIC-INTA, European Space Astronomy Centre campus, camino bajo del castillo s/n, E-28 692 Villanueva de la Cañada, Spain
| | - N Markova
- Institute of Astronomy with National Astronomical Observatory, Bulgarian Academy of Sciences, P.O. Box 136, 4700 Smoljan, Bulgaria
| | - F Najarro
- Centro de Astrobiología, CSIC-INTA, Carretera de Torrejón a Ajalvir km-4, E-28850 Torrejón de Ardoz, Madrid, Spain
| | - Ph Podsiadlowski
- Department of Physics, University of Oxford, Keble Road, Oxford OX1 3RH, UK.,Argelander-Institut für Astronomie der Universität Bonn, Auf dem Hügel 71, 53121 Bonn, Germany
| | - J Puls
- Ludwig-Maximilians-Universität München, Universitätssternwarte, Scheinerstrasse 1, 81679 München, Germany
| | - W D Taylor
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - J Th van Loon
- Lennard-Jones Laboratories, Keele University, Staffordshire ST5 5BG, UK
| | - J S Vink
- Armagh Observatory, College Hill, Armagh BT61 9DG, Northern Ireland, UK
| | - C Norman
- Johns Hopkins University, Homewood Campus, Baltimore, MD 21218, USA.,Space Telescope Science Institute, 3700 San Martin Drive, Baltimore, MD 21218, USA
| |
Collapse
|
28
|
Herrero A, Marcos M, Galindo P, Miralles JM, Corrales JJ. Clinical and biochemical correlates of male hypogonadism in type 2 diabetes. Andrology 2017; 6:58-63. [PMID: 29145714 DOI: 10.1111/andr.12433] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Revised: 08/09/2017] [Accepted: 08/29/2017] [Indexed: 01/21/2023]
Abstract
The origin of hypogonadism, a condition including both symptoms and biochemical criteria of androgen deficiency, in type 2 diabetes is poorly known. In a cross-sectional study of 267 unselected patients, we analyzed the potential correlation of several clinical and biochemical variables as well as chronic micro- and macrovascular diabetic complications with hypogonadism. Hypogonadism was present in 46 patients (17.2%) using a cutoff of total testosterone 10.4 nmol/L and in 31 (11.6%) with a cutoff of 8 nmol/L. Among these patients, hypogonadotropic hypogonadism was the most prevalent form (82.6%). Compared to eugonadal subjects, hypogonadal men had significantly lower glomerular filtration rate (67.1 ± 23.4 vs. 78.4 ± 24.6 mL/min/1.73 m2 , p = 0.005) and higher prevalence of chronic kidney disease (43.5% vs. 20.4%, p = 0.002), abnormal liver function tests (26.7% vs. 12%, p = 0.019), and psychiatric treatment (23.9% vs. 10.4%, p = 0.025). Total testosterone levels correlated inversely with age (R = -0.164, p = 0.007), fasting blood glucose (R = -0.127, p = 0.037), and triglycerides (R = -0.134, p = 0.029) and directly with glomerular filtration rate (R = 0.148, p = 0.015). Calculated free testosterone and bioavailable testosterone correlated directly with hemoglobin (R = 0.171, p = 0.015 and R = 0.234, p = 0.001, respectively). Multivariate logistic regression analysis, after adjusting for relevant confounding variables, showed that age >60 years (OR = 3.58, CI 95% = 1.48-8.69, p = 0.005), body mass index >27 kg/m2 (OR = 2.85, CI 95% = 1.14-7.11, p = 0.025), hypertriglyceridemia (OR = 2.16, CI 95% = 1.05-4.41, p = 0.035), glomerular filtration rate <60 mL/min/1.73 m2 (OR = 2.51, CI 95% = 1.19-5.29, p = 0.015), and abnormal liver function tests (OR = 3.57, CI 95% = 1.48-8.60, p = 0.005) were independently associated with male hypogonadism. Although older age, body mass index, and hypertriglyceridemia have been previously related to hypogonadism, our results describe that chronic kidney disease and abnormal liver function tests are independently correlated with hypogonadism in type 2 diabetic men.
Collapse
Affiliation(s)
- A Herrero
- Department of Medicine and Service of Endocrinology and Nutrition, University of Salamanca, University Clinical Hospital of Salamanca, Salamanca, Spain
| | - M Marcos
- Department of Medicine and Service of Internal Medicine, University of Salamanca, University Clinical Hospital of Salamanca, Salamanca, Spain
| | - P Galindo
- Department of Statistics, University of Salamanca, Salamanca, Spain
| | - J M Miralles
- Department of Medicine and Service of Endocrinology and Nutrition, University of Salamanca, University Clinical Hospital of Salamanca, Salamanca, Spain
| | - J J Corrales
- Department of Medicine and Service of Endocrinology and Nutrition, University of Salamanca, University Clinical Hospital of Salamanca, Salamanca, Spain.,Cancer Research Institute (IBMCC-CSIC/USAL) and Institute for Biomedical Research of the University of Salamanca, Salamanca, Spain
| |
Collapse
|
29
|
Bouwmeester S, Verkoeijen PPJL, Aczel B, Barbosa F, Bègue L, Brañas-Garza P, Chmura TGH, Cornelissen G, Døssing FS, Espín AM, Evans AM, Ferreira-Santos F, Fiedler S, Flegr J, Ghaffari M, Glöckner A, Goeschl T, Guo L, Hauser OP, Hernan-Gonzalez R, Herrero A, Horne Z, Houdek P, Johannesson M, Koppel L, Kujal P, Laine T, Lohse J, Martins EC, Mauro C, Mischkowski D, Mukherjee S, Myrseth KOR, Navarro-Martínez D, Neal TMS, Novakova J, Pagà R, Paiva TO, Palfi B, Piovesan M, Rahal RM, Salomon E, Srinivasan N, Srivastava A, Szaszi B, Szollosi A, Thor KØ, Tinghög G, Trueblood JS, Van Bavel JJ, van 't Veer AE, Västfjäll D, Warner M, Wengström E, Wills J, Wollbrant CE. Registered Replication Report: Rand, Greene, and Nowak (2012). Perspect Psychol Sci 2017; 12:527-542. [PMID: 28475467 PMCID: PMC5453400 DOI: 10.1177/1745691617693624] [Citation(s) in RCA: 82] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In an anonymous 4-person economic game, participants contributed more money to a common project (i.e., cooperated) when required to decide quickly than when forced to delay their decision (Rand, Greene & Nowak, 2012), a pattern consistent with the social heuristics hypothesis proposed by Rand and colleagues. The results of studies using time pressure have been mixed, with some replication attempts observing similar patterns (e.g., Rand et al., 2014) and others observing null effects (e.g., Tinghög et al., 2013; Verkoeijen & Bouwmeester, 2014). This Registered Replication Report (RRR) assessed the size and variability of the effect of time pressure on cooperative decisions by combining 21 separate, preregistered replications of the critical conditions from Study 7 of the original article (Rand et al., 2012). The primary planned analysis used data from all participants who were randomly assigned to conditions and who met the protocol inclusion criteria (an intent-to-treat approach that included the 65.9% of participants in the time-pressure condition and 7.5% in the forced-delay condition who did not adhere to the time constraints), and we observed a difference in contributions of -0.37 percentage points compared with an 8.6 percentage point difference calculated from the original data. Analyzing the data as the original article did, including data only for participants who complied with the time constraints, the RRR observed a 10.37 percentage point difference in contributions compared with a 15.31 percentage point difference in the original study. In combination, the results of the intent-to-treat analysis and the compliant-only analysis are consistent with the presence of selection biases and the absence of a causal effect of time pressure on cooperation.
Collapse
|
30
|
Buendia C, Herrero A, Sabater S, Batalla RJ. An appraisal of the sediment yield in western Mediterranean river basins. Sci Total Environ 2016; 572:538-553. [PMID: 27552132 DOI: 10.1016/j.scitotenv.2016.08.065] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 08/08/2016] [Accepted: 08/09/2016] [Indexed: 06/06/2023]
Abstract
The number of studies assessing soil erosion and sediment transport has increased with the aim of achieving sustainable land and water management. Mediterranean rivers have been the object of many of these studies due to their naturally high values of sediment fluxes and a higher vulnerability under future climate scenarios. In this context, we attempt to use empirical relationships to (i) further assess the relation between sediment yield and basin scale and (ii) provide an update on the main drivers controlling sediment yield in these particular river systems. For this purpose, sediment yield data (from reservoir sedimentation surveys and sediment transport records) was collected from >100 locations distributed across the western Mediterranean area, with basin areas ranging from 1 to 100,000km2. Quantile Regression analysis was used to assess the correlation between basin area and sediment yield, while additional basin-scale descriptors were related to sediment yield by means of multiple regression analysis. Results showed the complexity in the relationship between basin scale and sediment yield, with changes in supply conditions with increasing area introducing uncertainties in the correlation. Despite the large scatter, analysis pointed towards the same direction and area appeared to be the main constrain for the maximum value of sediment yield that can be found at a specific basin scale. Results from the multiple regression indicated that variables representing basin's physiography, climate and land use were highly correlated with the basins' sediment yield. Also, a better model performance was obtained when using total sediment yield instead of specific values (per unit area). Validation showed model instability, potentially due to data limitations and the use of catchments with varying characteristics. Overall, despite providing some insights on the correlation between sediment yield and basin-scale characteristics, validation prevented direct extrapolation of the model to other catchments.
Collapse
Affiliation(s)
- C Buendia
- Catalan Institute for Water Research-ICRA, 17003, Girona, Catalonia, Spain; Fluvial Dynamics Research Group-RIUS, University of Lleida, 25198 Lleida, Catalonia, Spain.
| | - A Herrero
- Catalan Institute for Water Research-ICRA, 17003, Girona, Catalonia, Spain; Fluvial Dynamics Research Group-RIUS, University of Lleida, 25198 Lleida, Catalonia, Spain
| | - S Sabater
- Catalan Institute for Water Research-ICRA, 17003, Girona, Catalonia, Spain; Institute of Aquatic Ecology, University of Girona, 17003 Girona, Catalonia, Spain
| | - R J Batalla
- Catalan Institute for Water Research-ICRA, 17003, Girona, Catalonia, Spain; Fluvial Dynamics Research Group-RIUS, University of Lleida, 25198 Lleida, Catalonia, Spain
| |
Collapse
|
31
|
Herrero A, Pinillos J, Sabio P, Martín JL, Garzón G, Gil Á. [Level at which control objectives are reached in patients in different population groups with type 2 diabetes]. Semergen 2016; 43:550-556. [PMID: 27889132 DOI: 10.1016/j.semerg.2016.09.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 05/13/2016] [Accepted: 09/07/2016] [Indexed: 10/20/2022]
Abstract
INTRODUCTION There is evidence of increased macro- and micro-vascular risk in diabetic patients. The objective of this study was to determine the level of control in patients in different population groups with type 2 diabetes. MATERIAL AND METHODS DESIGN Descriptive cross-sectional study. LOCATION Primary care. Madrid Health Service. Year: 2014. SUBJECTS Patients over 14 years with type 2 diabetes. Number of patientes: n=6674. MEASUREMENTS Variables on the degree of control (HbA1c, systolic blood pressure [SBP], diastolic blood pressure [DBP], LDL-c) and variables on patient characteristics (demographic, other cardiovascular risk factors, complications). RESULTS The mean age of patients with controlled HbA1c was 67.8 years vs. 62.9 years in the uncontrolled (P<.001). Patients diagnosed with hypertension have a higher percentage of control with respect to the undiagnosed in HbA1c, SBP, DBP and LDL-c: 51 vs. 37%, 62 vs. 43%, 75 vs. 47% and 57 vs. 44% respectively; diagnosed with dyslipidaemia: 51 vs. 39%, 60 vs. 49%, 70 vs. 56% and 56 vs. 46%. With a diagnosis of macroangiopathy: 46 vs. 45%, 58 vs. 54%, 71 vs. 62% and 15 vs. 60%. All differences were statistically significant (P<.001). Over 50% of patients without a diagnosis of hypertension had an SBP> 140mmHg or DBP> 90mmHg. Over 25% of patients with hypertension or DL and uncontrolled levels were not receiving drug treatment. CONCLUSION Control was improved in all groups, especially in younger patients, with particularly high cardiovascular risk by the presence of other cardiovascular risk factors or macroangiopathy. A significant percentage of patients with uncontrolled BP and cLDL were not diagnosed or receiving drug treatment.
Collapse
Affiliation(s)
- A Herrero
- Universidad Rey Juan Carlos, Madrid, España.
| | - J Pinillos
- Servicio de neumología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
| | - P Sabio
- Servicio de urgencias, Hospital Universitario del Henares, Madrid, España
| | - J L Martín
- Gerencia de Atención Primaria, Servicio Madrileño de Salud, Madrid, España
| | - G Garzón
- Universidad Rey Juan Carlos, Madrid, España
| | - Á Gil
- Departamento de Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, España
| |
Collapse
|
32
|
Herrero A, Sanllorente S, Reguera C, Ortiz M, Sarabia L. A new multiresponse optimization approach in combination with a D-Optimal experimental design for the determination of biogenic amines in fish by HPLC-FLD. Anal Chim Acta 2016; 945:31-38. [DOI: 10.1016/j.aca.2016.10.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/27/2016] [Accepted: 10/02/2016] [Indexed: 10/20/2022]
|
33
|
Murphy S, Scala A, Herrero A, Lorito S, Festa G, Trasatti E, Tonini R, Romano F, Molinari I, Nielsen S. Shallow slip amplification and enhanced tsunami hazard unravelled by dynamic simulations of mega-thrust earthquakes. Sci Rep 2016; 6:35007. [PMID: 27725733 PMCID: PMC5057117 DOI: 10.1038/srep35007] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 09/22/2016] [Indexed: 11/09/2022] Open
Abstract
The 2011 Tohoku earthquake produced an unexpected large amount of shallow slip greatly contributing to the ensuing tsunami. How frequent are such events? How can they be efficiently modelled for tsunami hazard? Stochastic slip models, which can be computed rapidly, are used to explore the natural slip variability; however, they generally do not deal specifically with shallow slip features. We study the systematic depth-dependence of slip along a thrust fault with a number of 2D dynamic simulations using stochastic shear stress distributions and a geometry based on the cross section of the Tohoku fault. We obtain a probability density for the slip distribution, which varies both with depth, earthquake size and whether the rupture breaks the surface. We propose a method to modify stochastic slip distributions according to this dynamically-derived probability distribution. This method may be efficiently applied to produce large numbers of heterogeneous slip distributions for probabilistic tsunami hazard analysis. Using numerous M9 earthquake scenarios, we demonstrate that incorporating the dynamically-derived probability distribution does enhance the conditional probability of exceedance of maximum estimated tsunami wave heights along the Japanese coast. This technique for integrating dynamic features in stochastic models can be extended to any subduction zone and faulting style.
Collapse
Affiliation(s)
- S Murphy
- Istituto Nazionale di Geofisica e Vulcanologia, Via di Vigna Murata, 00143 Rome, Italy
| | - A Scala
- Dipartimento di Fisica "Ettore Pancini", Università di Napoli Federico II, Italy.,Institut de Physique du Globe de Paris, France
| | - A Herrero
- Istituto Nazionale di Geofisica e Vulcanologia, Via di Vigna Murata, 00143 Rome, Italy
| | - S Lorito
- Istituto Nazionale di Geofisica e Vulcanologia, Via di Vigna Murata, 00143 Rome, Italy
| | - G Festa
- Dipartimento di Fisica "Ettore Pancini", Università di Napoli Federico II, Italy
| | - E Trasatti
- Istituto Nazionale di Geofisica e Vulcanologia, Via di Vigna Murata, 00143 Rome, Italy
| | - R Tonini
- Istituto Nazionale di Geofisica e Vulcanologia, Via di Vigna Murata, 00143 Rome, Italy
| | - F Romano
- Istituto Nazionale di Geofisica e Vulcanologia, Via di Vigna Murata, 00143 Rome, Italy
| | | | | |
Collapse
|
34
|
Lajusticia LR, Martín A, Marin AP, Aguado C, Gordoa TA, Herrero A, Maximiano C, Arevalo MG, Gallegos I, Villalobos L, Cassinello J, Garcia I, Arranz JE, Garcia-Donas J, Tafalla J, Torres G, Puente J, Grande Pulido E. Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): the Spanish Grupo Centro Experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Varela H, Villamañán E, Plasencia C, Romero JA, Ruano M, Balsa A, Herrero A. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects. J Clin Pharm Ther 2016; 41:306-9. [DOI: 10.1111/jcpt.12393] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2016] [Accepted: 04/01/2016] [Indexed: 11/28/2022]
Affiliation(s)
- H. Varela
- Pharmacy; La Paz University Hospital; Madrid Spain
| | | | - C. Plasencia
- Rheumatology; La Paz University Hospital; Madrid Spain
| | - J. A. Romero
- Pharmacy; La Paz University Hospital; Madrid Spain
| | - M. Ruano
- Pharmacy; La Paz University Hospital; Madrid Spain
| | - A. Balsa
- Rheumatology; La Paz University Hospital; Madrid Spain
| | - A. Herrero
- Pharmacy; La Paz University Hospital; Madrid Spain
| |
Collapse
|
36
|
Freire M, Sobrino C, De Sebastián M, Rossignoli A, Lara C, Herrero A. PS-018 Prescribing errors in hospitalised patients in a pulmonary unit. Effect of computerised order entry on their prevention. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
37
|
Villamañán E, González D, Armada E, Ruano M, Álvarez-Sala R, Herrero A. [The patents game. Generic and biosimilar drugs]. Rev Calid Asist 2016; 31:99-105. [PMID: 26542789 DOI: 10.1016/j.cali.2015.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Revised: 07/22/2015] [Accepted: 08/20/2015] [Indexed: 06/05/2023]
Abstract
The protection provided by patents on medicines has a limited duration. The expiry of patents expiration allows copies of the drugs to be released, competing with original. At first, they were identical to the original, known as generic drugs, but in recent years, due to the marketing of biological therapies and the expiry of many of their patents, biosimilar drugs have also emerged. These are not exact copies of the original, but, like generic drugs, biosimilar drugs have to demonstrate equivalence to the reference drugs in quality, safety and efficacy. Nevertheless, despite their importance and contribution to sustainability of health system, doctors are sometimes unaware of differences between them, and their impact in terms of clinical and economic effects. An attempt is made to review and clarify certain aspects often unknown by physicians, despite their involvement in their use.
Collapse
Affiliation(s)
- E Villamañán
- Servicio de Farmacia, Hospital Universitario La Paz, IdiPAZ , Madrid, España.
| | - D González
- Agencia Española de Medicamentos y Productos Sanitarios, Ministerio de Sanidad Política Social e Igualdad, Madrid, España
| | - E Armada
- Servicio de Cardiología, Hospital Universitario La Paz, IdiPAZ , Madrid, España
| | - M Ruano
- Servicio de Farmacia, Hospital Universitario La Paz, IdiPAZ , Madrid, España
| | - R Álvarez-Sala
- Servicio de Neumología, Hospital Universitario La Paz, IdiaPAZ, Madrid, España
| | - A Herrero
- Servicio de Farmacia, Hospital Universitario La Paz, IdiPAZ , Madrid, España
| |
Collapse
|
38
|
Cerqueiro J, González-Franco A, Montero-Pérez-Barquero M, Llácer P, Conde A, Dávila M, Carrera M, Serrado A, Suárez I, Pérez-Silvestre J, Satué J, Arévalo-Lorido J, Rodríguez A, Herrero A, Jordana R, Manzano L. Reducción de ingresos y visitas a Urgencias en pacientes frágiles con insuficiencia cardíaca: resultados del programa asistencial UMIPIC. Rev Clin Esp 2016; 216:8-14. [DOI: 10.1016/j.rce.2015.07.006] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Revised: 07/14/2015] [Accepted: 07/14/2015] [Indexed: 01/11/2023]
|
39
|
Cerqueiro J, González-Franco A, Montero-Pérez-Barquero M, Llácer P, Conde A, Dávila M, Carrera M, Serrado A, Suárez I, Pérez-Silvestre J, Satué J, Arévalo-Lorido J, Rodríguez A, Herrero A, Jordana R, Manzano L. Reduction in hospitalizations and emergency department visits for frail patients with heart failure: Results of the UMIPIC healthcare program. Rev Clin Esp 2016. [DOI: 10.1016/j.rceng.2015.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Ardid M, Camarena F, Felis I, Herrero A, Llorens C, Martínez-Mora J, Saldaña M. A compact array calibrator to study the feasibility of acoustic neutrino detection. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611603001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Gironés R, Alonso J, Arcusa A, Sánchez A, Barretina P, Borrega P, Cueva J, Alarcón J, Esteban M, Fuentes J, Garcia A, Garrigos L, Guerra E, Herrero A, Lainez N, Maximiano C, Martínez P, González-Martín A. 2774 ROSE study: A retrospective evaluation of clinical management of advanced ovarian cancer (AOC) in Spain by the Spanish Group for Research in Ovarian Cancer (GEICO). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31540-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Montserrat M, Sanz D, Juan T, Herrero A, Sánchez L, Calvo M, Pérez MD. Detection of peanut (Arachis hypogaea) allergens in processed foods by immunoassay: Influence of selected target protein and ELISA format applied. Food Control 2015. [DOI: 10.1016/j.foodcont.2015.01.049] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Herrero A, Romanowski A, Meelkop E, Caldart CS, Schoofs L, Golombek DA. Pigment-dispersing factor signaling in the circadian system ofCaenorhabditis elegans. Genes, Brain and Behavior 2015; 14:493-501. [DOI: 10.1111/gbb.12231] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 06/18/2015] [Accepted: 06/24/2015] [Indexed: 11/29/2022]
Affiliation(s)
- A. Herrero
- Laboratorio de Cronobiología, Departamento de Ciencia y Tecnología; Universidad Nacional de Quilmes; Buenos Aires Argentina
| | - A. Romanowski
- Laboratorio de Cronobiología, Departamento de Ciencia y Tecnología; Universidad Nacional de Quilmes; Buenos Aires Argentina
| | - E. Meelkop
- Animal Physiology and Neurobiology Section, Department of Biology; KU Leuven; Leuven Belgium
| | - C. S. Caldart
- Laboratorio de Cronobiología, Departamento de Ciencia y Tecnología; Universidad Nacional de Quilmes; Buenos Aires Argentina
| | - L. Schoofs
- Animal Physiology and Neurobiology Section, Department of Biology; KU Leuven; Leuven Belgium
| | - D. A. Golombek
- Laboratorio de Cronobiología, Departamento de Ciencia y Tecnología; Universidad Nacional de Quilmes; Buenos Aires Argentina
| |
Collapse
|
44
|
Lara C, Ruano M, Villamañán E, Pérez E, Balade L, Herrero A. PS-007 Survey on the use of vials and pens as insulin delivery devices in hospitalisation units. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
45
|
Casado G, Rueda C, Sierra A, Sobrino C, Varela H, Martinez L, Ruiz M, Freire M, Herrero A. PS-064 Chemotherapy administration safety in the outpatient oncology setting. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
46
|
Villamañán E, Lara C, Ruano M, Baumann T, Balade L, Varela H, Herrero A. GM-002 Improving medicines management in the hospital discharge setting through pharmacist intervention in the synchronisation of computer applications. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
47
|
Carenco C, Assenat E, Faure S, Duny Y, Danan G, Bismuth M, Herrero A, Jung B, Ursic-Bedoya J, Jaber S, Larrey D, Navarro F, Pageaux GP. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. Am J Transplant 2015; 15:678-86. [PMID: 25648361 DOI: 10.1111/ajt.13018] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 09/11/2014] [Accepted: 09/12/2014] [Indexed: 01/25/2023]
Abstract
Although increased rates of solid organ cancers have been reported following liver transplantation (LT), the impact of quantitative exposure to calcineurin inhibitors (CNI) remains unclear. We have therefore probed the relationship between the development of solid organ cancers following LT and the level of CNI exposure. This prospective single-center study was conducted between 1995 and 2008 and is based on 247 tacrolimus-treated liver transplant recipients who survived at least 1 year following surgery. The incidence of cancer was recorded, and the mean blood concentration of tacrolimus (TC) was determined at 1 and 3 years following LT. The study results indicate that 43 (17.4%) patients developed de novo solid cancers. Mean TC during the first year after LT was significantly higher in patients who developed solid organ tumors (10.3 ± 2.1 vs. 7.9 ± 1.9 ng/mL, p < 0.0001). Independent risks factors in multivariate analysis were tobacco consumption before LT (OR = 5.42; 95% CI [1.93-15.2], p = 0.0014) and mean annual TC during the first year after LT (p < 0.0001; OR = 2.01; 95% CI [1.57-2.59], p < 0.0001). Similar effects were observed in 216 patients who received tacrolimus continuously for ≥3 years. It appears therefore that CNI should be used with caution after LT, and that new immunosuppressive therapies could deliver significant clinical benefits in this regard.
Collapse
Affiliation(s)
- C Carenco
- Liver Transplantation Unit, Digestive Department, Saint Eloi University Hospital, University of Montpellier I, Montpellier, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Freire M, Sobrino C, De Sebastián M, Balade L, Bravo M, Lara C, Villamañán E, Herrero A. CP-005 Assessment of drug-drug interactions involving psychiatric agents in hospitalised patients. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
49
|
Villamañán E, Baumann T, Salvador O, Rueda C, Ruano M, Peinado R, Herrero A. PS-076 Prevalence of qt prolongation upon hospitalisation and the analysis of potentially related primary care treatments in cardiology patients. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
50
|
Casado G, Rueda C, Sierra A, Sobrino C, Varela H, Martinez L, Ruiz M, Freire M, Herrero A. PS-064 Chemotherapy administration safety in the outpatient oncology setting. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|